Patents by Inventor Francis W. Ruscetti

Francis W. Ruscetti has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DIAGNOSIS AND TREATMENT OF DISEASES OR DISORDERS ASSOCIATED WITH XENOTROPIC MURINE LEUKEMIA VIRUS
    Publication number: 20110117056
    Abstract: Methods of detecting, diagnosing, monitoring or managing an XMRV-related neuroimmune disease such as chronic fatigue syndrome or XMRV-related lymphoma such as mantle cell lymphoma in a subject are disclosed. These methods comprise determining presence, absence or quantity an XMRV immunopeptide, an XMRV antigen, or an XMRV nucleic acid in a sample from a subject. Therapeutic methods of treatment with anti-retroviral agents are also disclosed. Further disclosed are assays for testing compounds having activity against XMRV.
    Type: Application
    Filed: June 18, 2010
    Publication date: May 19, 2011
    Applicant: Whittemore Peterson Institute for Neuro-Immune Disease
    Inventors: Judy A. Mikovits, Vincent C. Lombardi, Sandra K. Ruscetti, Francis W. Ruscetti
  • SEROCONVERSION ASSAYS FOR DETECTING XENOTROPIC MURINE LEUKEMIA VIRUS-RELATED VIRUS
    Publication number: 20100167268
    Abstract: Methods of detecting, diagnosing, monitoring or managing an XMRV-related disease such as an XMRV-related neuroimmune disease such as chronic fatigue syndrome or an XMRV-related lymphoma such as mantle cell lymphoma in a subject are disclosed. These methods comprise determining presence, absence or quantity of antibodies against XMRV in a sample from a subject.
    Type: Application
    Filed: October 7, 2009
    Publication date: July 1, 2010
    Inventors: Judy A. Mikovits, Francis W. Ruscetti, Sandra K. Ruscetti
  • Large granular lymphocyte leukemia associated virus
    Patent number: 5891723
    Abstract: A large granular lymphocyte (LGL) leukemia related virus has been isolated and characterized from patients having LGL leukemia. The virus appears to be related to the family of retroviruses including HTLV-I, HTLV-I and Bovine Leukemia Virus. Nucleic acid sequences of the virus are presented.
    Type: Grant
    Filed: May 24, 1996
    Date of Patent: April 6, 1999
    Assignees: The Research Foundation of State University of New York, The United States of America as represented by The Department of Health and Human Services, Central New York Research Corporation
    Inventors: Thomas P. Loughran, Jr., Bernard J. Poiesz, Francis W. Ruscetti
  • Large granular lymphocyte leukemia associated virus
    Patent number: 5521083
    Abstract: A large granular lymphocyte (LGL) leukemia related virus has been isolated and characterized from patients having LGL leukemia. The virus appears to be related to the family of retroviruses including HTLV-I, HTLV-I and Bovine Leukemia Virus. Nucleic acid sequences of the virus are presented.
    Type: Grant
    Filed: May 13, 1994
    Date of Patent: May 28, 1996
    Assignee: The Research Foundation of State University of New York et al.
    Inventors: Thomas P. Loughran, Jr., Bernard J. Poiesz, Francis W. Ruscetti
  • Method for protecting bone marrow against chemotherapeutic drugs using transforming growth factor beta 1
    Patent number: 5278145
    Abstract: The present invention relates to a method for protecting hematopoietic stem cells from the myelotoxicity of chemotherapeutic drugs or radiation therapy, which comprises, administering to a subject a therapeutically effective amount of transforming growth factor beta 1 for protecting bone marrow from the myelotoxicity of chemotherapeutic drugs or radiation therapy. The TGF.beta.1 may be administered prior (e.g. 24 hours) to the administration of the chemotherapeutic drugs or radiation therapy. Preferably, the TGF.beta.1 is administered to the subject in an amount of about 5 .mu.g to 25 .mu.g per kg body weight. The patient or subject of the present invention may be a mammal (e.g. human, domestic animal such as horse, cow, dog, cat or pig) and is preferably a human being. The mode of administration is either by interfemoral arterial, interperitoneally or subcutaneously, and preferably is by injection.
    Type: Grant
    Filed: January 7, 1992
    Date of Patent: January 11, 1994
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Jonathan R. Keller, Francis W. Ruscetti, Robert Wiltrout